AAPL   367.34 (+0.89%)
MSFT   206.73 (+0.99%)
FB   234.30 (-1.37%)
GOOGL   1,465.00 (+1.60%)
AMZN   2,892.11 (+0.47%)
NVDA   385.77 (+1.20%)
CGC   16.42 (-0.30%)
MU   50.21 (+1.03%)
GE   6.89 (+2.23%)
TSLA   1,203.13 (+7.46%)
AMD   52.30 (-0.53%)
T   30.25 (+1.14%)
ACB   12.07 (-1.63%)
F   6.08 (+1.67%)
DIS   113.52 (+0.44%)
BAC   23.34 (+0.34%)
AAPL   367.34 (+0.89%)
MSFT   206.73 (+0.99%)
FB   234.30 (-1.37%)
GOOGL   1,465.00 (+1.60%)
AMZN   2,892.11 (+0.47%)
NVDA   385.77 (+1.20%)
CGC   16.42 (-0.30%)
MU   50.21 (+1.03%)
GE   6.89 (+2.23%)
TSLA   1,203.13 (+7.46%)
AMD   52.30 (-0.53%)
T   30.25 (+1.14%)
ACB   12.07 (-1.63%)
F   6.08 (+1.67%)
DIS   113.52 (+0.44%)
BAC   23.34 (+0.34%)
AAPL   367.34 (+0.89%)
MSFT   206.73 (+0.99%)
FB   234.30 (-1.37%)
GOOGL   1,465.00 (+1.60%)
AMZN   2,892.11 (+0.47%)
NVDA   385.77 (+1.20%)
CGC   16.42 (-0.30%)
MU   50.21 (+1.03%)
GE   6.89 (+2.23%)
TSLA   1,203.13 (+7.46%)
AMD   52.30 (-0.53%)
T   30.25 (+1.14%)
ACB   12.07 (-1.63%)
F   6.08 (+1.67%)
DIS   113.52 (+0.44%)
BAC   23.34 (+0.34%)
AAPL   367.34 (+0.89%)
MSFT   206.73 (+0.99%)
FB   234.30 (-1.37%)
GOOGL   1,465.00 (+1.60%)
AMZN   2,892.11 (+0.47%)
NVDA   385.77 (+1.20%)
CGC   16.42 (-0.30%)
MU   50.21 (+1.03%)
GE   6.89 (+2.23%)
TSLA   1,203.13 (+7.46%)
AMD   52.30 (-0.53%)
T   30.25 (+1.14%)
ACB   12.07 (-1.63%)
F   6.08 (+1.67%)
DIS   113.52 (+0.44%)
BAC   23.34 (+0.34%)
Log in

OTCMKTS:MDITCytocore Stock Price, Forecast & News

$0.06
0.00 (0.00 %)
(As of 07/2/2020 08:47 AM ET)
Add
Compare
Today's Range
$0.06
Now: $0.06
$0.06
50-Day Range
$0.03
MA: $0.04
$0.06
52-Week Range
$0.01
Now: $0.06
$0.08
Volume94 shs
Average Volume597 shs
Market Capitalization$5.02 million
P/E RatioN/A
Dividend YieldN/A
Beta2.67
MEDITE Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. MEDITE Cancer Diagnostics, Inc. is headquartered in Orlando, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MDIT
CUSIPN/A
Phone407-996-9630

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.81 million

Profitability

Miscellaneous

Employees69
Market Cap$5.02 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDIT and its competitors with MarketBeat's FREE daily newsletter.

Cytocore (OTCMKTS:MDIT) Frequently Asked Questions

How has Cytocore's stock been impacted by COVID-19 (Coronavirus)?

Cytocore's stock was trading at $0.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MDIT stock has increased by 46.3% and is now trading at $0.0585. View which stocks have been most impacted by Coronavirus.

Has Cytocore been receiving favorable news coverage?

News headlines about MDIT stock have been trending very negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cytocore earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Cytocore.

Who are some of Cytocore's key competitors?

What other stocks do shareholders of Cytocore own?

Who are Cytocore's key executives?

Cytocore's management team includes the following people:
  • Mr. Jeffrey Rencher, Chief Marketing & Bus. Devel. Officer (Age 52)
  • Ms. Susan Weisman, Consultant (Age 58)
  • Mr. Elmar A. Dave, Chief Exec. Officer

What is Cytocore's stock symbol?

Cytocore trades on the OTCMKTS under the ticker symbol "MDIT."

How do I buy shares of Cytocore?

Shares of MDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cytocore's stock price today?

One share of MDIT stock can currently be purchased for approximately $0.06.

How big of a company is Cytocore?

Cytocore has a market capitalization of $5.02 million and generates $6.81 million in revenue each year. Cytocore employs 69 workers across the globe.

What is Cytocore's official website?

The official website for Cytocore is www.medite-group.com.

How can I contact Cytocore?

Cytocore's mailing address is 4203 SW 34TH STREET, ORLANDO FL, 32811. The company can be reached via phone at 407-996-9630 or via email at [email protected]

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.